Baird Medical Showcases Microwave Ablation Technology at CIRSE 2026

COPENHAGEN, Denmark, Sept. 14, 2026 /CourierPR/ -- Baird Medical, a global medical technology company, showcased its Microwave Ablation (MWA) System at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress in Copenhagen. The event, held at the Bella Center, provided a platform for Baird Medical to engage with interventional radiologists and healthcare professionals from around the world.

The MWA System, designed to deliver precise and controlled ablation, features temperature control technology, stable 2.45 GHz microwave energy delivery, and a range of specialized probes. This technology is aimed at supporting different clinical applications in the treatment of solid tumors.

Baird Medical's MWA System is FDA-cleared for soft tissue ablation and is being launched in the U.S. primarily for the treatment of benign thyroid nodules. The company is expanding its minimally invasive technology portfolio, including IRE-based products and an AI-powered robotic ablation system.

Baird Medical's participation at CIRSE 2026 reflects the company's broader commitment to advancing minimally invasive treatment technologies and strengthening its engagement with physicians and healthcare institutions globally. The company has recently expanded its presence internationally, entering markets in Pakistan, Vietnam, and Argentina. As part of its global commercial footprint, Baird Medical's MWA solutions have been adopted by leading U.S. institutions and private practice groups, including the Mayo Clinic, Columbia University Medical Center, and The George Washington University Hospital.

The company's focus on providing reliable, precise, and versatile technologies is aimed at supporting physicians and improving treatment options for patients. Baird Medical remains committed to expanding its global commercial footprint and advancing its minimally invasive ablation technologies.